Want to join the conversation?
$DGX's 3Q15 reported operating income was $631MM, or 33.6% of revenues which benefited from the pre-tax gain of $334MM on the contribution to the clinical trials joint venture. In Oct., new companion diagnostic solutions were separately announced for two recent FDA approved therapies for non-small cell lung cancer.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.